[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pre-diabetes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pre-diabetes":56},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,48,0,25,[9,43,70,107,136,170,212,237,259,286,315,339,367,388,415,440,466,487,511,537,558,588,617,644,664],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100548844","effectiveness-of-the-brazilian-diabetes-prevention-program-100548844",false,"NCT06426277","Effectiveness of the Brazilian Diabetes Prevention Program","Effectiveness of the Diabetes Prevention Program on the Incidence of Type 2 Diabetes Mellitus Among Brazilian Individuals: Randomized Clinical Trial (PROVEN-DIA Study)","PROVEN-DIA","Inclusion Criteria\n\n* Be 18 years or older (no maximum age for being eligible)\n* Have a body mass index (BMI) between 18,5 and 34,9kg\u002Fm²\n* Have, at least, one electronic device (includes any of the following devices):\n\n  * Computer\n  * Laptop\u002Fnotebook\n  * Tablet\n  * Smartphone\n* Have access to internet (broadband, 3G, 4G, 5G, among others) Without previous nutritional counseling (within the 6 months prior to recruitment\u002Frandomization\u002Fintervention) Without supervision by a Physical Education Professional (Personal Trainer) in the past 6 months\n* Living near the research center (at maximum 60 minutes)\n* Diagnosis of prediabetes defined as two HbA1c measurements between 5.7% and 6.4% collected 7 to 90 days apart.\n\nExclusion Criteria:\n\n* Diagnosis of Diabetes Mellitus (including current or recent use, within three months, of glucose-lowering medication)\n* Underlying disease likely to limit life expectancy and\u002For increase the risk of interventions influencing the risk of developing T2D\n* Diagnosis of Renal Disease\n* Diagnosis of Pulmonary Disease\n* Gastrointestinal Disease\n* Secondary prevention for Cardiovascular Disease\n* Endocrine Diseases\n* Weight loss exceeding 10% in the last 6 months (except postpartum-related)\n* Uncontrolled Hypertension\n* Diagnosis of Polycystic Ovary Syndrome (self-reported)\n* Patients undergoing treatment for Tuberculosis (except those using isoniazid \\[INH\\] as prophylaxis)\n* Presence of diseases that may severely reduce life expectancy or the ability to participate in the study\n* Pregnant or breastfeeding women\n* Severe psychiatric disorders that, in the opinion of the clinical team, hinder participation in the program\n* Acute or chronic excessive alcohol consumption\n* Congestive Heart Failure (CHF) with a New York Heart Association Functional Class (NYHA) \\> 2\n* Need for referral to a cardiologist according to the Physical Activity Readiness Questionnaire (PAR-Q)\n* Current or recent participation (within the last six months) in another clinical trial that impacts the interventions and\u002For is associated with the study outcomes (in case of doubt, contact the coordinating center)\n* Likely relocation away from the research collaborating center within the next 3 years\n* Another household member is a participant or a team member of the PROVEN-DIA study\n* Unwillingness to accept treatment assignment by randomization and\u002For refusal to participate in the study (signing the Informed Consent Form)\n* Continuous use of the following medications:\n\nCorticosteroids other than topical, ophthalmic, or inhaled preparations Antineoplastic agents Psychoactive agents Other medications.\n\n• Participant from the pilot Randomized Clinical Trial (Brazilian Diabetes Prevention Program: Pilot Study (PROVEN-Dia), NCT05689658)","ALL","18 Years",{"count":21,"type":22},1305,"ESTIMATED","INTERVENTIONAL",[25],"NA","The aim of this multicenter, randomized controlled trial is to assess the effectiveness of the Brazilian Diabetes Prevention Program (delivered face-to-face or via e-health) in preventing type 2 diabetes (T2D) in at least 1,305 adults at high risk of T2D over a 3-year follow-up period. Our outcomes include the incidence of T2D, body weight (kg), BMI, glycemic biomarkers, use of antidiabetic drugs, the proportion of individuals achieving controlled glycemia or HbA1c levels without medication, diet quality, moderate-to-vigorous physical activity (min\u002Fweek), prevalence of physical inactivity, sleep quality, perceived stress, alcohol consumption, smoking, and quality of life. In addition, social, cultural, educational, and geographical factors at the community level will be analyzed throughout the follow-up to determine their association with the incidence of T2D.",[28,29],"Prediabetic State","Pre Diabetes","RECRUITING","2026-06-22",{"date":33,"type":34},"2026-06-25","ACTUAL",{"date":36,"type":34},"2024-12-01",{"date":38,"type":22},"2029-12-31",{"name":40,"class":41},"Beneficência Portuguesa de São Paulo","OTHER",2,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100642303","7-ketolithocholic-acid-in-prediabetes-100642303","NCT07650123","7-Ketolithocholic Acid in Prediabetes","A Multicentre, Double Blind, Placebo Controlled, Clinical Trial to Investigate the Effects and Tolerability of 7-Ketolithocholic Acid, a Novel Food, Associated to Diet and Physical Activity, in Lowering Fasting Plasma Glucose (FPG) Levels in Subjects With Pre-diabetes.","Inclusion Criteria:\n\n1. Male and female participants aged ≥18 years and ≤70 years.\n2. Ability and willingness to provide written informed consent.\n3. Diagnosis of prediabetes, defined by the following metabolic criteria:\n\n   * Impaired fasting glucose (IFG): fasting plasma glucose levels between 100 and 125 mg\u002FdL.\n   * Impaired glucose tolerance (IGT): plasma glucose levels between 140 and 199 mg\u002FdL measured 2 hours after a standard oral glucose tolerance test (OGTT).\n   * Elevated HbA1c: HbA1c values between 5.7% and 6.4% (or 42 and 47 mmol\u002Fmol).\n4. Body mass index (BMI) in the range 25-31 kg\u002Fm2 (inclusive).\n5. Willingness to strictly comply with a low-glycaemic, hypocaloric diet during the study period and maintain a food diary.\n6. Willingness to comply with recommended physical activity during the study period and maintain an activity diary.\n7. Women of childbearing potential must agree to not become pregnant during the study and to use effective contraception (according to Recommendations related to contraception and pregnancy testing in clinical trials.\n\nExclusion Criteria:\n\n1. Previous or current diagnosis of diabetes mellitus.\n2. Presence of hypertension, defined as blood pressure \\>130\u002F85 mmHg.\n3. Hypertriglyceridemia, defined as fasting blood triglyceride levels ≥ 200 mg\u002FdL.\n4. LDL cholesterol ≥ 190 mg\u002FdL.\n5. Current treatment with oral hypoglycaemic agents or use of supplements with hypoglycaemic effects.\n6. Use of any medication (self-medication or prescription medication) or supplementation potentially acting on glucose and lipid parameters within 28 days before entry in the study (or at least 5 times the respective elimination half-life, whichever is longer).\n7. Any medical condition or treatment that, in the opinion of the investigator, could interfere with the study outcomes or participant safety.\n8. Use of vitamin K antagonist anticoagulant drugs (such as warfarin).\n9. Pregnancy or breast-feeding.\n10. Any other condition that would preclude adherence to the study protocol or informed consent process, including, but not limited, to active or uncontrolled metabolic, endocrine, cardiovascular, renal, hepatic, pulmonary, gastrointestinal, neurological, endocrinological, immunological, or psychiatric disease.\n11. Subjects with any history of hypersensitivity to the product under study or its excipients (please refer to Appendix B for listing of ingredients).","70 Years",{"count":52,"type":22},100,[25],"7-Ketolithocholic Acid, a naturally occurring bile acid, is a novel food currently under investigation for potential metabolic benefits, including glucose-lowering effects. This study aims to evaluate the efficacy and safety of 7-Ketolithocholic Acid, administered alongside a low-glycaemic, hypocaloric diet, and increased physical activity in reducing fasting plasma glucose and other metabolic parameters in subjects with prediabetes. Demonstrating a clinically meaningful glucose-lowering effect would support its potential role in early intervention to prevent or delay the onset of type 2 diabetes.",[56],"Pre-diabetes",[58],"7-KLCA, bile acid, novel food, fasting plasma glucose (FPG), glycated haemoglobin (HbA1c)","2026-06-10",{"date":61,"type":34},"2026-06-16",{"date":63,"type":22},"2026-06",{"date":65,"type":22},"2027-06",{"name":67,"class":68},"ICE S.p.A.","INDUSTRY",8,{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":77,"minAge":19,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":90,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100601479","sisters-for-heart-health-a-community-health-worker-initiative-for-improving-heart-health-in-farmworker-women-100601479","NCT07111026","Sisters for Heart Health: A Community Health Worker Initiative for Improving Heart Health in Farmworker Women","Inclusion Criteria:\n\n* Self-identified female employed as a farmworker;\n* Fluent in Spanish or English verbal literacy\n* Planning to be in the geographic area for a minimum of 6 months.\n\nExclusion Criteria:\n\n* Cognitive or psychological impairment precluding informed consent and\u002For active participation in the study due to substance use, neurologic, or other disorder\n* Pregnant or breastfeeding.",true,"FEMALE","50 Years",{"count":80,"type":22},269,[25],"The goal of this hybrid Type 1 effectiveness-implementation trial is to test the extent to which a peer support and community resource navigation intervention improves psychological well-being, addresses non-biologic drivers of health (access to healthcare, supportive services, nutrition, housing stability, transportation, chronic stress, social support), and thus reduces cardiometabolic risk among rural, low-income farmworker women aged 18-50 years. The main questions it aims to answer are:\n\n* If and to what extent does the intervention reduce stress, social isolation, and psychological distress by improving social support and access to needed resources?\n* If and to what extent does the intervention improve cardiometabolic health, measured by the American Heart Association's Life's Essential 8 (LE8) score?\n\nResearchers will compare the CHW-led Sisters for Heart Health intervention to a Basic intervention (LE8 assessment and resource information) to assess the effect of peer support and community resource navigation on heart health outcomes.",[84,85,86,87,29,88,89],"Occupational Stress","Gender Related Stress","Social Isolation","Hypertension","Diabetes","Obesity",[91,92,93,94,95,96],"occupational stress","gender related stress","social isolation","psychological stress","cardiometabolic health","non biological drivers of health","2026-06-04",{"date":99,"type":34},"2026-06-08",{"date":101,"type":34},"2025-09-16",{"date":103,"type":22},"2028-12",{"name":105,"class":41},"Emory University",1,{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":116,"conditions":117,"keywords":123,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":106},"100555510","milk-for-diabetes-prevention-100555510","NCT06513026","Milk for Diabetes Prevention","Inclusion Criteria:\n\n* LNP genotype (LCT gene rs4988235, GG genotype)\n* History of pre-diabetes, defined as fasting blood glucose 100-125 mg\u002FdL and\u002For hemoglobin A1c (HbA1c) 5.7-6.4% and have not been diagnosed with diabetes nor take diabetes medication (pre-diabetes determined at most recent study visit \\[for HCHS\u002FSOL participant\\] or most recent medical chart or self-report \\[for other participant\\])\n* Drink ≤1 cup milk\u002Fday\n* Basic computer or smartphone skills\n* Can speak and read English fluently\n\nExclusion Criteria:\n\n* Diabetes diagnosis\n* Taking anti-diabetes medication\n* Cancer, cardiovascular disease (CVD), or life-threatening illness\n* Known milk allergy\n* Has severe GI symptoms after drinking milk\n* History of GI surgery\n* Had a double mastectomy\n* Smoking\n* More than 1 alcoholic beverage\u002Fday\n* Pregnant or breastfeeding\n* Colonoscopy in last 2 weeks\n* Antibiotics in last 3 months\n* Taking probiotics or fiber supplements (if taking, must be able to stop taking during study)\n* Taking laxatives, stool softeners, anti-diarrheal (if taking, must be able to stop taking during study)\n* Taking lactase pills (if taking, must be able to stop taking)\n* Participating in extreme dieting program\n* Planning extended travel that would prevent participation in study\n* Taking medication that must be taken separate from calcium or dairy products",{"count":114,"type":22},40,[25],"Individuals with lactase non-persistence (LNP; determined by a functional variant in the LCT gene \\[rs4988235, GG genotype\\]) are susceptible to lactose intolerance in adulthood due to deficiency of lactase, the enzyme which digests milk lactose sugars. However, many LNP individuals still drink ≥1 cup of milk daily. Recent analysis in the Hispanic Community Health Study\u002FStudy of Latinos (HCHS\u002FSOL) found that consumption of 1 serving (cup) of milk\u002Fday was associated with \\~30% lower risk of type 2 diabetes among LNP individuals, but not among individuals with lactase persistence (LP). This beneficial effect might be partially explained by favorable alterations in gut microbiota and related metabolites associated with higher milk consumption among LNP individuals. Based on these observational study findings, the investigator team proposes to conduct a randomized, controlled trial of lactose-containing vs. lactose-free milk in LNP individuals with pre-diabetes, to comprehensively investigate the effects of milk intake on the gut microbiome and glycemic outcomes.",[118,119,120,121,122],"Lactose Intolerance","Lactose Intolerant","Lactase Persistence","Pre-Diabetes","Diabetes Mellitus, Type 2",[124,125,126],"Lactose","Lactose-free","Lactase Non Persistence","2026-05-21",{"date":129,"type":34},"2026-05-26",{"date":131,"type":34},"2026-05-15",{"date":133,"type":22},"2028-04",{"name":135,"class":41},"Albert Einstein College of Medicine",{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":143,"targetDuration":145,"studyType":146,"phases":4,"briefSummary":147,"conditions":148,"keywords":153,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":4},"100637631","cgm-experience-preferences--blood-glucose-parameters-100637631","NCT07607015","CGM Experience, Preferences & Blood Glucose Parameters","Instara™-1 Dual Perspectives on Continuous Glucose Monitoring: Understanding Patient Experience and Healthcare Professional Preferences","Inclusion Criteria:\n\n* Subjects to provide written informed consent prior to any study procedures being performed\n* Subjects with age 18 and above both male and female\n* Diagnosed with Diabetes Miletus Type I, Type II and\u002For GDM\n* Comfortable using smart phone, access to internet along with Bluetooth connectivity throughout the study duration.\n* Subjects (Patients) on oral or injectable anti-diabetic medications, (in case of insulin, patient must be on insulin from last 3 months )\n* Subjects (HCPs) healthy, Pre-diabetes or Diabetes Miletus (any type)\n\nExclusion Criteria:\n\n* History of hypersensitivity to any of the active or inactive ingredients of the CGM device used in the trial, and\u002For history of significant allergic skin reactions.\n* Presence of severe diabetes complications e.g. retinopathy, acute metabolic crisis, etc.\n* History of active\u002F acute renal and\u002For hepatic failure.\n* Patients who have been admitted to the hospital in the past 3 months for diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state.\n* History of critical illness or incapacitated patients\n* History of acute psychiatric disorder or exacerbation of chronic psychiatric disorder.\n* History or presence of a medical condition or disease that in the investigator's opinion would embarrass glycemic control and completion of the study.\n* Medical conditions that require patients to undergo frequent radiation\u002F imaging procedures for example CT, MRI and X rays\n* History of known hematological disorders such as Sickle Cell Disease \\& Trait, Thalassemia, Hemolytic Anemias (e.g., G6PD deficiency, autoimmune), Iron Deficiency Anemia\n* Patients on high doses of acetaminophen (\\>1 gram every 6 hours), ascorbic acid supplements (e.g., \\> 500-1000 mg\u002Fday), IV sorbitol, steroids and aspirin which can alter the readings on the CGM device.",{"count":144,"type":22},75,"3 Months","OBSERVATIONAL","This is an open-label, prospective, multicenter observational study designed to evaluate the perceived benefits, device experience, preference, and glucose-related parameters associated with the Instara-1 Continuous Glucose Monitoring device. The study will include patients with diabetes and healthcare professionals. Patients will use Instara- 1 and will be followed up to assess device experience, glucose parameters, and diabetes-related quality of life. Healthcare professionals will evaluate device experience and preference, including comparison with FreeStyle Libre 2.",[149,150,151,152,29],"Diabete Mellitus","Type2diabetes","type1diabetes","Gestational Diabetes",[154,155,156,157,158,159,160],"CGM","Glucose monitoring","Time in range","estimated HbA1c","Time above range","Time below range","Diabetes Quality of life","NOT_YET_RECRUITING","2026-05-19",{"date":129,"type":34},{"date":165,"type":22},"2026-09-10",{"date":167,"type":22},"2027-08-10",{"name":169,"class":68},"Getz Pharma",{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":18,"minAge":178,"maxAge":50,"enrollmentInfo":179,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":182,"conditions":183,"keywords":192,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":106},"100605783","the-groceries-aimed-at-increasing-nutrition-study-100605783","NCT07167004","The GRoceries Aimed at Increasing Nutrition Study","Prompting a Switch From Refined Grains to Whole Grains in an Online Grocery Store Using Marketing Nudges and Financial Incentives","GRAINS","Inclusion Criteria:\n\n* Age 45 - 70 years.\n* Able to provide consent.\n* Resident of Philadelphia, Bucks, Delaware, Chester, or Montgomery Counties in Pennsylvania.\n* Consume \\\u003C5 servings of whole grains per week.\n* Use online grocery shopping at least once per month.\n* Have access to a credit or debit card to pay for groceries purchased.\n* Have reliable internet access.\n* Speak English.\n* Penn Medicine patient diagnosed with prediabetes or diabetes (identified using ICD-10 codes R73.03, E11).\n\nExclusion Criteria:\n\n* Does not meet all the inclusion criteria.\n* Not able to speak English.\n* Not able to provide consent.","45 Years",{"count":180,"type":22},216,[25],"Only 2% of Americans meet the recommended levels of whole grain consumption, despite its association with reduced risk of type 2 diabetes. This study aims to assess if consumers with prediabetes or type 2 diabetes can be encouraged to switch from buying refined grain products to whole grain products when shopping for groceries online. The study will use personalized marketing strategies, with or without discounts which adjust based on purchasing behavior, to promote whole grain consumption.",[184,185,186,56,187,188,189,190,191],"Type 2 Diabetes","Type II Diabetes Mellitus","Type II Diabetes","Pre-diabetic","Pre-diabetic State","Type 2 Diabetes Mellitus (T2DM)","Type 2 Diabetes Mellitus","Type 2 Diabetes (T2DM)",[193,194,195,196,197,198,199,200,201,202,203,204],"chronic disease","diabetes","diabetes mellitus","type II diabetes","type 2 diabetes","pre-diabetes","prediabetes","whole grains","behavioral economics","marketing nudges","financial incentives","food is medicine",{"date":162,"type":34},{"date":207,"type":34},"2025-10-14",{"date":209,"type":22},"2027-02-16",{"name":211,"class":41},"University of Pennsylvania",{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":220,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":222,"conditions":223,"keywords":224,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":236},"100582347","ogtt-at-home-using-cgm-vs-at-the-clinic-100582347","NCT06862128","OGTT at Home Using CGM vs at the Clinic","Oral Glucose Tolerance Test at Home With Continuous Glucose Monitoring vs Standard Clinic-based Testing","OGTT-CGM","Inclusion Criteria:\n\n* Prediabetes indicated by ≥2 of the following values, measured at separate occasions or through different analyses during the past 2 years:\n* \\- Fasting venous plasma glucose ≥6.1 but ≤6.9 mmol\u002FL\n* \\- Non-fasting venous plasma glucose ≥7.8 but ≤11.0 mmol\u002FL\n* \\- HbA1c ≥39 but ≤47 mmol\u002Fmol\n* Access to a smart phone which is compatible with the CGM application and has working Bluetooth connectivity\n* Ability to read and respond to online instructions and questionnaires in Swedish.\n\nExclusion Criteria:\n\n* T2D indicated by ≥2 of the following values, measured at different occasions or through different analyses:\n* \\- Fasting venous plasma glucose ≥7.0 mmol\u002FL\n* \\- Non-fasting venous plasma glucose value ≥11.1 mmol\u002FL\n* \\- HbA1c ≥48 mmol\u002Fmol\n* Previous bariatric surgery e.g., gastric by-pass or gastric sleeve surgery\n* Body mass index \\\u003C20 kg\u002Fm2\n* Body weight \\\u003C43 kg\n* Current pregnancy\n* Need of regular use of GLP-1 receptor agonists, SGLT-2 inhibitors, acetaminophen or ascorbic acid supplements during the study period\n* Fear of needle sticks\n* Shift work during the study period\n* Involvement in the study design, data collection, analysis, or participant recruitment.",{"count":144,"type":22},[25],"This randomized, crossover study evaluates the feasibility and accuracy of a self-administered oral glucose tolerance test (OGTT) at home using continuous glucose monitoring (CGM) compared to a standard clinic-based OGTT. Participants with prediabetes will undergo both home-based and clinic-based OGTTs, with glucose levels measured via CGM and venous plasma glucose. The primary outcome is the correlation between CGM-based glucose values and standard OGTT results. Secondary outcomes include diagnostic agreement, metabolic hormone associations, and feasibility of home-based testing as a diagnostic tool for dysglycemia.",[56,88],[56,88,225,226,227],"Oral glucose tolerance test","Continuous glucose monitoring","Glucose",{"date":162,"type":34},{"date":230,"type":34},"2025-06-11",{"date":232,"type":22},"2040-12-31",{"name":234,"class":235},"Linkoeping University","OTHER_GOV",3,{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":18,"minAge":245,"maxAge":19,"enrollmentInfo":246,"targetDuration":247,"studyType":146,"phases":4,"briefSummary":248,"conditions":249,"keywords":4,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":4},"100636707","impact-of-continuous-glucose-monitoring-and-education-intervention-on-glycemic-control-and-behavioral-changes-in-pre-diabetic-adolescents-100636707","NCT07569185","Impact of Continuous Glucose Monitoring and Education Intervention on Glycemic Control and Behavioral Changes in Pre-Diabetic Adolescents","A Pilot Study Evaluating the Impact of Continuous Glucose Monitoring and Education Intervention on Glycemic Control and Behavioral Changes in Pre-Diabetic Adolescents","PreDiA-CGM","Inclusion Criteria:\n\n* • At least 13 years of age\n\n  * No older than 17 years of age (up to 18th birthday)\n  * Access to a smart-device compatible with a continuous glucose monitor application and wearable biosensor\n  * Diagnosed prediabetes, defined as any of the following:\n\n    * Fasting plasma glucose of 100- 125 mg\u002FdL\n    * 2-hour glucose level on oral glucose tolerance test (OGTT):140-199 mg\u002FdL\n    * HbA1c 5.7%-6.4%\n\nExclusion Criteria:\n\n* • Previous diagnosis of Prader Willi Syndrome\n\n  * Previous diagnosis of hypothalamic obesity\n  * Previous diagnosis of intellectual disability\n  * Previous or planned bariatric surgery\n  * Current use of medication is known to impact weight\n  * Previous diagnosis of diabetes mellitus\n  * Hemoglobin A1c \\>6.5%\n  * Non-English speaking","13 Years",{"count":7,"type":22},"20 Weeks","Prediabetes is a condition wherein blood sugar levels are elevated but not sufficiently high enough to diagnose type 2 diabetes mellitus (T2D). Prediabetes is a critical risk factor for the development of T2D in pediatric populations. This progression can occur over a short period of time, limiting the efficacy and impact of existing interventions and recommendations targeting this population. There is growing evidence on the use of continuous glucose monitors (CGMs) in adult prediabetic populations to prevent the development of T2D, though this intervention has not been thoroughly investigated in pediatric populations.\n\nThe investigators are proposing a pilot study of 25 prediabetic adolescents enrolled in a 20-week study. For the initial 10 weeks of the study, the participants will go without CGMs and undergo clinically recommended education on their condition as standard of care. In the 10 weeks following, participants will be given a CGM to wear and instructions on its use. Surveys will be issued to all participants over the entirety of the study to follow behaviors surrounding food and physical activity.",[29],"2026-04-28",{"date":252,"type":34},"2026-05-06",{"date":254,"type":22},"2026-06-01",{"date":256,"type":22},"2027-07-30",{"name":258,"class":41},"University of Arizona",{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":266,"enrollmentInfo":267,"targetDuration":4,"studyType":23,"phases":269,"briefSummary":270,"conditions":271,"keywords":274,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":106},"100613688","comparing-a-healthy-beef-centric-diet-to-a-healthy-us-style-diet-on-metabolic-health-outcomes-in-pre-diabetic-adults-100613688","NCT07269847","Comparing a Healthy Beef-Centric Diet to a Healthy U.S.-Style Diet on Metabolic Health Outcomes in Pre-Diabetic Adults","A Randomized Study to Compare the Effect of a Healthy Beef-Centric Diet to a Healthy U.S.-Style Dietary Pattern on Inflammation and Other Metabolic Health Outcomes in a Metabolic Syndrome and\u002For Pre-Diabetic Population","Inclusion Criteria:\n\n* Participant must be 18 - 74 years of age (inclusive) at the time of signing the informed consent.\n* Have a BMI range of 23.0 - 39.9 kg\u002Fm2 (inclusive).\n* In otherwise generally good health as determined by the investigator.\n* Have blood hs-CRP levels equal to or greater than 2.0 mg\u002FL at screening.\n* Have the following conditions at screening:\n\n  1. Pre-diabetes (defined as an HbA1c of 5.7-6.4% \\[inclusive\\]), and\u002For\n  2. MetS, i.e., have 3 of the 5 following metabolic criteria:\n\n     * A waist circumference of more than 40 inches (102 cm) in men and 35 inches (88 cm) in women\n     * Serum triglycerides level of 150 mg\u002FdL (1.7 mmol\u002FL) or greater\n     * Reduced HDL cholesterol, less than 40 mg\u002FdL (1.0 mmol\u002FL) in men or less than 50 mg\u002FdL (1.3 mmol\u002FL) in women\n     * Elevated fasting glucose of 100 mg\u002FdL (5.6 mmol\u002FL) or greater\n     * Blood pressure values of systolic 130 mmHg or higher or diastolic 85 mmHg or higher\n* Report low to moderate levels of physical activity, as defined by a \"low\" or \"moderate\" activity classification on the IPAQ-SF (if ≤69 YOA) or IPAQ-E (if ≥70 YOA) at screening.\n* Consume meat-based protein as a part of their normal diet and regularly consume beef.\n* Not currently using, defined as ≤ 3 uses in the past 3 months prior to Visit 2, any nicotine containing products (patches, gums, vapes, etc.), and willing to abstain for 14 days before Visit 2 until the last procedure.\n* Have maintained a stable, self-reported body weight for at least 6 months prior to screening (maximum ±10% change in self-reported body weight).\n* Willing and able to consume all aspects of either study dietary intervention.\n* Willing to adhere to all study dietary intervention prohibitions and restrictions.\n* Have maintained consistent dietary habits, including medication and supplement intake, and lifestyle for the last 3 months before screening and agree to maintain them throughout the study (unless required per the restrictions).\n* Agree to follow the restrictions on concomitant treatments.\n* Agree to follow the restrictions on lifestyle.\n* Agree to avoid pregnancy throughout the study if of childbearing potential by using any preferred contraceptive method.\n* Willing and able to agree to the requirements of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, and carry out all study-related procedures.\n\nExclusion Criteria:\n\n* Individuals who are lactating, planning to become pregnant during the study, or pregnant as confirmed by a positive pregnancy test at Visit 2.\n* Have a known sensitivity, intolerability, or allergy to any of the components of the study dietary interventions and\u002For CGM sensor.\n* Have followed and maintained a ketogenic, Mediterranean, low-carbohydrate, vegetarian, vegan or any other special diet in the 3 months prior to screening.\n* Have been diagnosed with Type I or II diabetes or thyroid disease.\n* Have blood pressure of ≥ 160 systolic or ≥ 100 diastolic mmHg.\n* Have a history or current diagnosis of eating disorders such as anorexia or bulimia.\n* Have current symptoms, or symptoms within the past 7 days, of an acute infection (e.g., fever, respiratory symptoms such as persistent cough or difficulty breathing), that may influence study outcomes as assessed by the investigator.\n* Have medical condition(s) known to interfere with absorption, distribution, metabolism, or excretion of protein, fat, or micronutrients (e.g., Crohn's disease, short bowel, acute or chronic pancreatitis, or pancreatic insufficiency).\n* Have a history of gallbladder disease (e.g., cholelithiasis, cholecystitis), cholecystectomy, gout, or kidney stones.\n* Have a history of heart\u002Fcardiovascular disease, renal disease (dialysis or renal failure), hepatic impairment\u002Fdisease, immune disorders and\u002For immunocompromised (i.e., HIV\u002FAIDS).\n* Have a history of cancer (except localized skin cancer without metastases or in situ cervical cancer) with recovery occurring within 5 years before the screening visit.\n* Are receiving treatments for or have been hospitalized in the last 12 months for psychiatric disorders (e.g., depression, bipolar disorder, schizophrenia, etc.).\n* Major surgery in 3 months prior to screening or planned major surgery during the study.\n* Have a history of alcohol or substance abuse in the 12 months prior to screening (including having been hospitalized for such an in-patient or out-patient intervention program) or use that in the opinion of the investigator may be a concern for the study.\n* Current enrollment or past participation in another study with either any product(s) with at least one active ingredient or a dietary intervention, within 28 days before screening or longer, if the previous test product is deemed by the investigator to have lasting effects that might influence the eligibility criteria or outcomes of current study.\n* Living in the same household as another currently enrolled participant in the present study.\n* Any other medical condition\u002Fsituation or use of medications\u002Fsupplements\u002Ftherapies that, in the opinion of the investigator, may adversely affect the participant's ability to participate in the study or its measures or pose a significant risk to the participant.","74 Years",{"count":268,"type":22},56,[25],"This randomized study will be conducted to compare the effect of a healthy beef-centric diet to a healthy U.S.-style dietary pattern on inflammation and other metabolic health outcomes in a metabolic syndrome and\u002For pre-diabetic population.",[272,273,121],"Metabolic Syndrome (MetS)","Inflammation",[275,276,273,277,121],"Healthy Beef-Centric Diet","Healthy U.S.-Style Dietary Pattern","Metabolic Syndrome",{"date":279,"type":34},"2026-05-04",{"date":281,"type":34},"2026-02-10",{"date":283,"type":22},"2026-09-03",{"name":285,"class":68},"National Cattlemen's Beef Association, a contractor to the Beef Checkoff",{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":293,"enrollmentInfo":294,"targetDuration":4,"studyType":23,"phases":296,"briefSummary":297,"conditions":298,"keywords":300,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":308,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":106},"100484219","stand-up-for-your-health-with-a-sit-stand-desk-100484219","NCT05585190","Stand up for Your Health With a Sit-stand Desk","Stand Up for Your Health: A Randomized Study","Inclusion Criteria:\n\n1. Overweight or obese (body mass index of 25 kg\u002Fm2 or higher)\n2. Employees with \"sedentary\" jobs, defined as spending at least 75% of their (8 hours or more) workday sitting at a desk (at home or in an office)\n3. Defined as \"at-risk\" for diabetes, defined as either:\n\n   1. Prediabetes (HbA1c of 5.7% to 6.4%) or a fasting glucose of 100 to 125 mg\u002FdL\n   2. Having one or more additional risk factors: (beyond BMI\\>25)\n\n      * Age 45 years or older\n      * Family history of diabetes mellitus in a first-degree relative\n      * Physical inactivity (no structured exercise activity)\n      * History of gestational diabetes, hypertension, or dyslipidemia\n      * African American, Alaska Native, American Indian, Asian American, Hispanic\u002FLatino, Native Hawaiian, or Pacific Islander ethnicity\n\nExclusion Criteria:\n\n1. Established cardiovascular disease (myocardial infarction, coronary stent, coronary artery bypass grafting, cardiac transplant, or angina)\n2. Established congestive heart failure or cardiomyopathy\n3. Established peripheral vascular disease\n4. Established diabetes (HbA1c ≥ 6.5% or on diabetes medications or insulin)\n5. Chronic musculoskeletal disorders involving the lower extremities, such as arthritis of the knees or hips, or regular use of ambulatory assist devices such as a walker or cane\n6. Neuropathy of any etiology\n7. Positional syncope or history of orthostasis\n8. Less than 4 days\u002Fweek at any single office (or work-from-home) location.\n9. Current use of a standing desk for work\n10. Tobacco use within the previous 12 months\n11. Current illicit drug use or excessive alcohol use (defined as more than 14 drinks\u002Fweek for women, more than 28 drinks\u002Fweek for men)\n12. Steroid use ≥21 days\u002Fyear\n13. Fasting triglyceride level ≥ 500 mg\u002FdL\n14. Thyroid disease\n15. Uncontrolled or untreated hypertension(\\>150\u002F90 mm Hg)\n16. Pregnant or lactating (or plans to become pregnant in the next 6 months)\n17. LDL cholesterol ≥ 190mg\u002FdL\n18. Currently enrolled or plans to diet or join a weight loss program over the next 6 months.\n19. Non-English speaker","79 Years",{"count":295,"type":22},198,[25],"More than 84 million - or 1 out of every 3 U.S. adults - have prediabetes, a condition that if not treated often leads to type 2 diabetes within five years. Average medical expenditures among diabetics are about 2.3 times higher than expenditures for people without diabetes. Physical inactivity and elevated body mass index (BMI) are major risk factors for the disease. Sedentary behavior is becoming increasingly prevalent with the growth of a 'work from home' culture, most recently driven by the COVID-19 pandemic. Cross-sectional epidemiologic data report significant associations between high amounts of sedentary (sitting) time and prevalent cardiovascular disease and diabetes. In our pilot study of 15 subjects with sedentary office jobs, 6 months of sit-stand desk use resulted in a 23% improvement in insulin resistance, most substantial in those who decreased daily sitting by over 90 minutes\u002Fday. Additional improvements in vascular endothelial function and triglyceride levels were seen without any change in exercise activity, step counts, or body weight. These findings not only corroborate epidemiologic findings on this topic but suggest causality and warrant a randomized control trial.\n\nThe investigators hypothesize that adult subjects at-risk for diabetes will improve insulin sensitivity, metabolic and vascular (endothelial) health with a sit-stand desk intervention at work (whether in the office or at home), in the context of a randomized, controlled trial. The investigators will randomize 198 sedentary office workers with a BMI≥25 at risk for type 2 diabetes mellitus in a 1:1:1 ratio of three groups: (a) sit-stand desk intervention targeting 2 hours standing per day; (b) sit-stand desk intervention targeting 3 hours standing per day; or (c) control arm over 6 months. The block randomization design will allow for important dose-response analyses.\n\nThe investigators will objectively quantify standing time, sedentary time, sedentary bouts, daily steps, and exercise activity times using a compact and re-usable accelerometer that adheres to the subject's thigh. This will provide objective assessments of activity levels and sedentary times for 7 full days each at baseline, 3 and 6 months. The device is equipped with an inclinometer to classify posture (sitting verses standing).",[29,89,277,299],"Sedentary Behavior",[29,89,277,301,302,303,304,305,306,307],"Cardiovascular","Sit-stand desk","Physical Activity","Overweight","Sedentary","Standing desk","Insulin resistance",{"date":279,"type":34},{"date":310,"type":34},"2023-02-06",{"date":312,"type":22},"2027-12-31",{"name":314,"class":41},"Medical College of Wisconsin",{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":322,"targetDuration":324,"studyType":146,"phases":4,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":106},"100632601","qatar-cardiometabolic-retrospective-cohort-analysis-using-artificial-intelligence-100632601","NCT07515807","Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence","QCRC-AI","Inclusion Criteria:\n\n* Age ≥ 18\n* Qatari and Arab participants\n* Participants admitted for Acute Coronary Syndrome (ACS) or Acute Heart Failure (AHF)\n* Metabolic disease: Diabetes (HbA1C ≥ 6.5% or any HbA1C if a patient is on an antidiabetic agent) or pre-diabetes: 5.7% ≤ HbA1c ≤ 6.4%\n\nExclusion Criteria:\n\n* Non-Qatari or non-Arab participants\n* Non-diabetic: HbA1C \\\u003C 5.7%\n* This chart review involves no direct interaction with individuals. Prisoners are not a focus of this study, and incarceration status is not identifiable in the records reviewed.",{"count":323,"type":22},10000,"2 Years","Cardiovascular disease is the leading cause of death worldwide, and individuals with diabetes or other cardiometabolic conditions are at increased risk of adverse cardiovascular outcomes. Although advances in prevention and treatment have reduced cardiovascular events globally, cardiometabolic disease continues to represent a significant health burden, particularly in regions with high diabetes prevalence. In Qatar and other Gulf Cooperation Council countries, the prevalence of diabetes and obesity is increasing, contributing to a high proportion of participants presenting with acute coronary syndrome who have type 2 diabetes or prediabetes. This observational study will use electronic medical record data from patients hospitalized at the Heart Hospital with acute coronary syndrome and a concomitant diagnosis of diabetes or prediabetes. The study will assess trends in cardiovascular risk factors and cardiovascular events, including readmission and mortality. An artificial intelligence component will be used to develop and validate machine learning based risk prediction models to forecast adverse cardiovascular outcomes in participants with cardiometabolic disease. These models will integrate clinical, biochemical, imaging, and other non-invasive data routinely collected during participants care to identify predictors of cardiovascular events.",[327,328,184,29,329],"Cardio Vascular Disease","Acute Coronary Syndromes (ACS)","Artifical Intelligence","2026-04-15",{"date":332,"type":34},"2026-04-21",{"date":334,"type":22},"2026-07-16",{"date":336,"type":22},"2030-07-16",{"name":338,"class":41},"Weill Cornell Medical College in Qatar",{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":76,"sex":18,"minAge":345,"maxAge":50,"enrollmentInfo":346,"targetDuration":4,"studyType":23,"phases":348,"briefSummary":350,"conditions":351,"keywords":352,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":42},"100566594","phase-4-normal-weight-diabetes-adipocyte-directed-therapy-with-pioglitazone-or-tirzepatide-100566594","NCT06657209","Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide","Inclusion Criteria:\n\nNormal-Weight Diabetes (NWD) Group:\n\n1. Age: 30 to 70 years old.\n2. Diagnosis of Type 2 Diabetes (T2D): Based on a previous diagnosis or confirmed by laboratory testing at screening (A1c \\> 5.7% or fasting glucose \\> 100 mg\u002FdL).\n3. HbA1c Range: Between 5.7% and 8%, with a stable medication or lifestyle regimen for at least 3 months.\n4. BMI: Between 19 and 24.9 kg\u002Fm².\n5. Diabetes Medications: All diabetes medications are allowed, except insulin and pioglitazone. GLP-1 receptor agonists are permitted if the dose has been stable for 3 months.\n6. Stable Body Weight: Body weight must have been stable (no more than 2 kg change) over the last 3 months.\n\nNormal-Weight Control (NWC) Group:\n\n1. Age: 30 to 70 years old.\n2. No Diagnosis of Diabetes: Fasting plasma glucose \\\u003C 100 mg\u002FdL and A1c \\\u003C 5.7%, with no history of glucose-lowering medications.\n3. BMI: Between 19 and 24.9 kg\u002Fm².\n4. Stable Body Weight: No more than 2 kg change over the past 3 months. -\n\nExclusion Criteria:\n\n1. Pregnancy or Lactation: Women who are pregnant, planning to become pregnant, or breastfeeding are excluded due to potential risks to the fetus or infant.\n2. Prior Use of Pioglitazone: Participants who have previously used pioglitazone are excluded to avoid confounding effects of prior drug exposure.\n3. Unstable Body Weight: Individuals with a body weight change of more than 2 kg in the last 3 months are excluded to ensure stable metabolic conditions.\n4. Liver or Kidney Disease: Participants with significant liver disease (ALT \\> 3x upper limit of normal) or renal disease (creatinine \\> 1.5 mg\u002FdL) are excluded due to potential safety risks.\n5. Congestive Heart Failure or Fluid Overload History: These conditions are exclusionary due to the risk of fluid retention with pioglitazone.\n6. Uncontrolled Hypertension: Blood pressure \\> 160\u002F90 mmHg excludes participants due to increased cardiovascular risk.\n7. Active Cancer: Individuals with a diagnosis of cancer in the past 3 years (except for skin cancer) are excluded.\n8. Chronic Inflammatory Diseases: Excluded due to potential effects on metabolic measurements.\n9. Use of Weight Loss Medications: Those currently taking weight loss medications are excluded to prevent confounding effects on body weight and metabolic function.\n10. Bariatric Surgery or Liposuction History: Participants who have had weight-loss surgeries or liposuction are excluded due to alterations in fat tissue and metabolic profiles.\n11. Insulin Use: Participants using insulin are excluded to focus on non-insulin-dependent diabetes.\n12. Active Psychiatric Disease or Eating Disorders: Individuals with these conditions are excluded due to potential impacts on study compliance and data integrity.\n13. Substance Abuse: Participants with a history of substance abuse are excluded for similar reasons.\n\n    \\-","30 Years",{"count":347,"type":22},104,[349],"PHASE4","This study is to investigate how adipocyte (fat cell) function and fat distribution differ between individuals with normal-weight type 2 diabetes (NWD), those with overweight type 2 diabetes (OWD), and normal-weight controls without diabetes (NWC). The study will assess whether adipocyte-directed therapies, specifically pioglitazone and tirzepatide, can improve insulin resistance, adipocyte function, and fat distribution in individuals with NWD. By analyzing the biological mechanisms underlying adipocyte dysfunction, the study aims to provide insights into novel treatment strategies for improving metabolic health in normal-weight individuals with type 2 diabetes.",[122,88,184,29],[353,194,198,354,355,356,357,358],"metabolism","insulin sensitivity","insulin resistance","insulin resistant","insulin sensitive","adipocyte",{"date":360,"type":34},"2026-04-20",{"date":362,"type":34},"2025-01-13",{"date":364,"type":22},"2027-12-15",{"name":366,"class":41},"Stanford University",{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":76,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":106},"100586939","glycemic-metrics-and-patterns-in-people-with-and-without-prediabetes-100586939","NCT06921902","Glycemic Metrics and Patterns in People With and Without Prediabetes","Observation and Identification of Glycemic Metrics and Patterns in People With and Without Prediabetes (PREMAP)","PREMAP","Inclusion Criteria:\n\n* Subject must be at least 18 years of age.\n* Subject must be willing and able to provide written signed and dated informed consent.\n\nExclusion Criteria:\n\n* Subject has a diagnosis of type 1 diabetes, type 2 diabetes, or gestational diabetes.\n* Subject is known to be currently practicing a low-carbohydrate or ketogenic diet at the time of enrollment.\n* Subject is known to be pregnant at the time of enrollment.\n* Subject has known allergy to medical grade adhesive, isopropyl alcohol and\u002For ethyl alcohol used to disinfect skin.\n* Subject is currently on any form of treatment indicated for the treatment of diabetes.\n* Subject is currently on any form of medication indicated for weight loss.",{"count":376,"type":22},2000,"The FreeStyle Libre 3 Continuous Glucose Monitoring (FSL3) System is used to characterize the glycemic profiles of people with and without a prediabetes diagnosis.",[29],"2026-04-06",{"date":381,"type":34},"2026-04-09",{"date":383,"type":34},"2025-02-28",{"date":385,"type":22},"2026-12",{"name":387,"class":68},"Abbott Diabetes Care",{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":392,"acronym":393,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":23,"phases":397,"briefSummary":398,"conditions":399,"keywords":402,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":106},"100627081","evidence-based-intervention-for-diabetes-prevention-100627081","NCT07443995","Evidence-based Intervention for Diabetes Prevention","EID","Inclusion Criteria:\n\n* Men and women 18 years or older\n* Diabetes risk score \\> 5\n* BMI \\>=25kg\u002Fm\\^2\n* Arabic or English speaking\n* Able to read and write in Arabic or English\n* Access to a smartphone\n* Provide informed consent\n\nExclusion Criteria:\n\n* Prevalent diabetes\n* Prior participation in a diabetes prevention program\n* Taking FDA-approved weight loss medications\n* Pregnant or lactating",{"count":396,"type":22},30,[25],"The goal of this behavioral intervention trial is to develop strategies to decrease the incidence of diabetes within the UAE. The investigators will investigate the effectiveness of a group-based telehealth intervention facilitated by a health coach in adults at risk for developing diabetes who live in the UAE.\n\nThe investigators will conduct a single-arm feasibility trial of the Evidence-based Intervention for Diabetes prevention among thirty adults with prediabetes. All participants will receive 12 weekly virtual intervention sessions over the course of three months, facilitated by a trained DPP lifestyle coach who is from the same cultural community and can deliver the material in either Arabic or English.\n\nThe primary feasibility measure is acceptability, as measured by intervention session attendance. Other outcome assessments will be conducted at baseline and three months at NYU Abu Dhabi, where study staff will assess weight, hemoglobin A1c, diet, and physical activity.",[56,400,401],"Lifestyle Risk Reduction","Diet Prevention of Metabolic Diseases",[198,403,404,405],"behavioral intervention","diet","physical activity","2026-02-24",{"date":408,"type":34},"2026-03-02",{"date":410,"type":22},"2026-04",{"date":412,"type":22},"2027-08",{"name":414,"class":41},"New York University",{"id":416,"slug":417,"hasResults":12,"nctId":418,"briefTitle":419,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":76,"sex":18,"minAge":421,"maxAge":422,"enrollmentInfo":423,"targetDuration":4,"studyType":23,"phases":425,"briefSummary":426,"conditions":427,"keywords":428,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":106},"100443210","phase-4-the-effects-of-mirabegron-and-tadalafil-on-glucose-tolerance-in-prediabetics-100443210","NCT05051436","The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics","Inclusion Criteria:\n\n* Hemoglobin A1C between 5.7 and 6.4\n* Body mass index between 27 and 45\n\nExclusion Criteria:\n\n* Diabetes\n* Chronic use of any antidiabetic medications\n* Any unstable medical condition\n* Use of steroids or daily use of NSAIDS\n* History of chronic inflammatory conditions\n* Use of anticoagulants\n* Contraindications to the use of mirabegron or tadalafil\n* Any condition deemed risky by the study physician","35 Years","65 Years",{"count":424,"type":22},96,[349],"The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo.",[56,89],[429,430],"Tadalafil","Mirabegron","2026-02-02",{"date":433,"type":34},"2026-02-03",{"date":435,"type":34},"2021-12-13",{"date":437,"type":22},"2026-08",{"name":439,"class":41},"Philip Kern",{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":446,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":448,"enrollmentInfo":449,"targetDuration":4,"studyType":23,"phases":451,"briefSummary":453,"conditions":454,"keywords":455,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":106},"100607490","phase-2-long-term-impact-of-time-restricted-eating-on-parameters-of-cardiometabolic-health-100607490","NCT07189234","Long Term Impact of Time-Restricted Eating on Parameters of Cardiometabolic Health","TIMET 2.0 - Long Term Impact of Time-Restricted Eating on Parameters of Cardiometabolic Health","TIMET 2","Inclusion criteria:\n\n1. Age: 18-75 years\n2. HbA1c: 5.7% to 7.0%\n3. Metabolic syndrome (must meet 3 criteria):\n\n   1. Elevated systolic blood pressure ≥ 130 mm Hg or diastolic blood pressure ≥ 85 mm Hg OR an antihypertensive therapy)\n   2. Elevated waist circumference:\n\n      \\- In Asians: ≥ 90 cm in men, ≥80 cm in women In all other races: ≥ 102 cm in men, ≥ 88 cm in women\n   3. Fasting plasma triglycerides ≥ 150 mg\u002FdL, or on drug treatment for elevated triglycerides d) Reduced High-density lipoprotein (HDL)- cholesterol \\\u003C 40 mg\u002FdL in males or \\\u003C 50 mg\u002F\u002FdL in females, or drug treatment for reduced HDL-cholesterol e) Fasting glucose ≥ 100 mg\u002FdL\n4. Own a smartphone (Apple iOS or Android OS)\n5. Baseline eating period ≥12 hour\u002Fday\n6. Patients on a stable dose of cardiovascular medications (HMG CoA reductase inhibitors \\[statins\\]), other lipid-modifying drugs (including over-the-counter drugs such as red yeast rice and fish oil), or anti-hypertensive drugs) for at least 1 month are allowed.\n7. Patients on GLP-1 R agonists, SGLT2 inhibitors, or Metformin must be on stable doses for at least 3 months.\n\nExclusion criteria:\n\n1. Use of sulfonylurea or insulin.\n2. HbA1C \\> 7.0%\n3. Pregnant or breastfeeding. Anyone of reproductive age will receive pregnancy test prior to DXA scan.\n4. Caregiver for a dependent requiring frequent nocturnal care \u002F sleep interruptions.\n5. Shift workers with variable (e.g. nocturnal) hours.\n6. Frequent travel to different time zones during the study period.\n7. Active tobacco use or illicit drug use or history of treatment for alcohol abuse.\n8. History of major adverse cardiovascular event within the past year (acute coronary syndrome, percutaneous coronary intervention, coronary artery bypass graft surgery, hospitalization for congestive heart failure, stroke\u002Ftransient ischemic attack).\n9. History of surgical intervention for weight management within the past 2 years, or longer if deemed unsafe following review by medical investigators\n10. Uncontrolled arrhythmia (i.e. rate -controlled atrial fibrillation \u002F atrial flutter are not exclusion criteria)\n11. History of thyroid disease requiring dose titration of thyroid replacement medication(s) within the past 3 months (i.e. hypothyroidism on a stable dose of thyroid replacement therapy is not an exclusion).\n12. History of adrenal disease.\n13. History of malignancy undergoing active treatment, except non-melanoma skin cancer.\n14. Known history of type 1 diabetes.\n15. History of an eating disorder.\n16. History of cirrhosis.\n17. History of stage 4 or 5 chronic kidney disease or requiring dialysis.\n18. Currently enrolled in a weight-loss or weight-management program.\n19. On a special or prescribed diet for other reasons (e.g. Celiac disease).\n20. Uncontrolled psychiatric disorder (including history of hospitalization for psychiatric illness).\n21. Inability or unwillingness to utilize the mCC app throughout study duration.","75 Years",{"count":450,"type":22},140,[452],"PHASE2","In a randomized controlled trial, the investigators intend to measure the health impact of time restricted eating (TRE) in patients with metabolic syndrome (with elevated blood pressure and at least 2 of the following: increased waist circumference, abnormal cholesterol levels, elevated triglycerides, and elevated fasting glucose levels), who habitually eat more than 12 hours every day. Patients will be randomly assigned to a control group (standard of care) or intervention group (TRE).",[277,56],[456,457],"Time Restricted Eating","Fasting","2026-01-29",{"date":431,"type":34},{"date":461,"type":34},"2025-10-23",{"date":463,"type":22},"2029-01-06",{"name":465,"class":41},"University of California, San Diego",{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":18,"minAge":472,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":23,"phases":475,"briefSummary":476,"conditions":477,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":106},"100456545","lifestyle-patterns-and-glycemic-control-100456545","NCT05224986","Lifestyle Patterns and Glycemic Control","Inclusion Criteria:\n\n* Pre-diabetic kg\u002Fm2 (hemoglobin A1c 5.7-6.9%)\n* 25 years or older\n* BMI between 25-39.9 kg\u002Fm2\n* Sleep duration ≥6 hours a night assessed with wrist actigraphy (for 14 nights)\n* Variable bedtime, SD≥45 minutes.\n\nExclusion Criteria:\n\n* Chronic Kidney Disease (GFR\\\u003C60)\n* Uncontrolled hypertension (≥160\u002F100 mmHg)\n* Obstructive Sleep Apnea\n* Psychiatric or neurological disorder\n* Prevalent cardiovascular disease\n* Dyslipidemia (triglycerides≥200 mg\u002FdL)\n* Medications that affect insulin sensitivity, glucose concentrations, and body weight\n* Non-day or rotating shift workers\n* Travel across time zones\n* Active participation in weight loss program or within past 3 months\n* Current or past alcohol\u002Fdrug abuse","25 Years",{"count":474,"type":22},34,[25],"The goal of the proposed study is to evaluate the feasibility and initial efficacy of stabilizing lifestyle behaviors to improve glucose control and body composition in patients with pre-diabetes.\n\nThe investigator proposes that following stable lifestyle behaviors will improve patients' glucose control, body composition, and liver fat. The results from this study has the potential to impact clinical practice and patient care.",[56],"2026-01-27",{"date":480,"type":34},"2026-01-28",{"date":482,"type":34},"2022-01-19",{"date":484,"type":22},"2026-07-31",{"name":486,"class":41},"Columbia University",{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":18,"minAge":494,"maxAge":495,"enrollmentInfo":496,"targetDuration":4,"studyType":23,"phases":498,"briefSummary":499,"conditions":500,"keywords":501,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":509,"locationsCount":42},"100621509","continuous-glucose-monitoring-cgm-in-prediabetes-100621509","NCT07371546","Continuous Glucose Monitoring (CGM) in Prediabetes","Continuous Glucose Monitoring (CGM) in Prediabetes: A Mixed-Methods Study Exploring Behavioural Impact, Patient Experiences and Provider Perspectives","Patient Participants\n\nInclusion Criteria:\n\n1. Singaporean Citizen or Permanent Resident\n2. Age 21 - 69 years old\n3. Clinical diagnosis of prediabetes defined as a fasting glucose of 6.1-6.9 mmol\u002FL and\u002For 2-hour glucose level of 7.8-11.0 mmol\u002FL after an oral glucose tolerance test (Appropriate Care Guide, 2021)\n\n   a. Can be conservatively managed, or medically managed with metformin\n4. Owns a mobile phone that can download the Singapore FreeStyle LibreLink App\n5. Expressed willingness to use participate in the study, use the devices according to the study protocol during the study period, and to sign informed consent.\n\nExclusion Criteria:\n\n1. Pregnant or planned pregnancy within the next six months\n2. Physical limitation that prevents the patient from engaging in physical exercise\n3. Cognitively impaired based on diagnosis of dementia or mild cognitive impairment (MCI) in the electronic health records (EHR)\n4. Not adequately proficient in English\n5. Currently enrolled in another study or program that involves weight loss or dietary modifications, or novel therapeutic drug or device\n6. Planned surgery in the next six months\n7. Not able to use smartphone or the Singapore FreeStyle LibreLink App despite coaching\n8. Any end-stage disease with life prognosis of \\\u003C 2 years\n9. Patients who are not willing or are not able to commit to the entire study program\n\nHealthcare Providers (HCP) Participants HCPs from Pasir Ris Polyclinic who self-reported to have treated adults with prediabetes will be enrolled for the interviews.","21 Years","69 Years",{"count":497,"type":22},76,[25],"Part 1 and 2 of study (For Patient Participants) The purpose of this study is to examine if the wearing of a medical device called a continuous glucose monitor (CGM) can guide adults with prediabetes modify their behaviors and manage their health, compared to traditional health coaching. Prediabetes means the study participants have a higher-than-normal blood sugar level which is not high enough to be considered type 2 diabetes yet but will put them at risk of developing it. CGM measures glucose levels without the participants having to prick fingers and involves wearing a small sensor on the back of the arm day and night which allows viewing of glucose levels on the mobile phone with a painless 1 second scan.\n\nThis is the first time the investigators are trying to do research using CGM for adults with prediabetes. the study team want to learn how practical it is to do such a study. The study will explore if wearing of a CGM sensor makes a difference in terms of health outcomes compared to regular health coaching. It also aims to understand the users' experience with the CGM system.\n\nThis study targets to recruit 76 participants from Pasir Ris Polyclinic.\n\nPart 1 of the study uses a research method called a randomized controlled trial. Participants who consent to join will be allocated to one of two groups based on chance. Half of the participants will receive the CGM sensor in addition to health coaching. This is called the intervention group. The other half of the participants will receive health coaching alone. This is called the control group. Participants in both groups will continue regular follow-up with their own primary care physicians.\n\nThere will be 3 study touchpoints, which will mainly be at Pasir Ris Polyclinic.\n\n1. Baseline visit:\n\n   * Receive health coaching that will take 20-30 minutes.\n   * Complete questionnaires about socio-demographic details, diet and physical activity which will take 20-30 minutes.\n   * Measure weight, body mass index (BMI), and waist circumference.\n   * Past medical history and medications will be retrieved from the electronic medical records.\n   * If the participants are in the intervention group, the study team will assist them to apply the Abbott Freestyle Libre continuous glucose monitoring (CGM) sensor and link it to their smartphone. The study team will also set up the LibreLink app and Libreview account.\n2. 1-month touchpoint\n\n   * Complete follow up questionnaires to assess any changes in the diet and physical activity.\n   * This touchpoint may be conducted either face-to-face or via a phone call.\n3. 6-month touchpoint\n\n   * Complete final questionnaires about the lifestyle.\n   * Measure weight, BMI and waist circumference again\n   * Uninstall the LibreLink app and Libreview account.\n\nPart 2 of the study is an in-depth interview to understand the experiences of the participants using the Abbott Freestyle Libre CGM System. This part of the study will be conducted either during the 3rd study touchpoint or on another day (within 9 months from start of intervention). The interview will last 60 minutes and will be audio-recorded. Questions asked will be regarding the general experience using the CGM, any difficulties with following the study instructions and suggestions to improve the study.\n\nPart 3 of study for Healthcare Providers Participants (HCP):\n\nThe purpose of this study is to assess the effects of CGM on adults with prediabetes and to explore the facilitators and barriers of using CGM in prediabetes management from both patients and healthcare providers. The study aims to understand the perspectives of primary care providers on the potential benefits, challenges, and feasibility of integrating CGM into prediabetes management. The findings will help pave the way for broader integration of CGM technology into public health programs targeting specific populations at high risk of diabetes to improve health outcomes.\n\nIf the participants agree to participate, they will be invited to fill in a data collection form on the demographics, qualifications and clinical experience. This will take 20-30 minutes. The participants will be interviewed either individually or in a group with other of their colleagues from the same polyclinic. During the interview, the researcher will ask questions pertaining to their experiences with prediabetes management, knowledge of CGM and their views of the potential challenges and opportunities in the utilization of CGM by prediabetic adults. The interviews will be audio recorded. participation in the study will last approximately 60 minutes.",[56],[502,226,503,56],"Primary care","Behavioural change","2026-01-19",{"date":480,"type":34},{"date":507,"type":34},"2025-10-16",{"date":385,"type":22},{"name":510,"class":41},"SingHealth Polyclinics",{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":12,"sex":18,"minAge":494,"maxAge":517,"enrollmentInfo":518,"targetDuration":4,"studyType":23,"phases":520,"briefSummary":521,"conditions":522,"keywords":524,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":106},"100612370","preventing-diabetes-impact-of-an-emr-based-intervention-for-enhanced-pre-diabetes-management-in-primary-care-100612370","NCT07252700","Preventing Diabetes: Impact of an EMR-Based Intervention for Enhanced Pre-Diabetes Management in Primary Care","Inclusion Criteria for study population (EMR based analytic cohort):\n\n* All adults aged 21 to 59 years with prediabetes who attend any of the eight participating polyclinics during the study period will be included in the EMR-based analytic cohort.\n* Prediabetes is defined as impaired fasting glucose or impaired glucose tolerance according to standard clinical criteria, with either diagnosis documented in the EMR problem list or visit diagnosis.\n* Individuals with a prior diagnosis of diabetes will be excluded.\n\nInclusion Criteria for patient surveys:\n\n* Adults aged 40-59 years\n* Diagnosed with prediabetes (impaired fasting glucose or impaired glucose tolerance)\n* Receiving routine follow-up care at NUP polyclinics\n* Able to provide written informed consent\n* Able to complete questionnaires in English\n\nExclusion criteria for patient surveys:\n\n* Prior diagnosis of diabetes mellitus or gestational diabetes\n* Severe acute or chronic liver or kidney disease\n* Pregnancy\n* Cognitive impairment\n* Inability to communicate in English\n\nInclusion Criteria for clinician surveys:\n\n* All clinicians that consult patients in National University Polyclinics\n* No exclusion criteria specified for clinicians","59 Years",{"count":519,"type":22},6000,[25],"The goal of this study is to find out if adding electronic medical record (EMR) prompts helps prevent people with pre-diabetes from developing diabetes. It will also look at how these prompts affect doctor and patient behaviors.\n\nThe main questions are:\n\nDoes it improve follow-up care, such as blood tests, referrals, and medication? Does the EMR prompt reduce the number of patients who progress to diabetes within six months?\n\nResearchers will compare clinics that use EMR prompts with clinics that do not.\n\nParticipants will:\n\nReceive usual care for pre-diabetes at their polyclinic In some clinics, doctors will see EMR prompts suggesting tests, referrals, and medication Complete surveys about their health and lifestyle at different time points",[29,523],"Diabetes (DM)",[199,525,526,527],"primary care","electronic medical records (EMR)","OurPractice Advisories","2026-01-12",{"date":530,"type":34},"2026-01-14",{"date":532,"type":34},"2025-09-02",{"date":534,"type":22},"2028-03-31",{"name":536,"class":41},"Lynette Goh",{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":4},"100614463","what-is-the-role-of-triglyceride-glucose-index-as-a-predictive-marker-for-insulin-resistance-in-pre-diabetic-chronic-kidney-disease-patients-100614463","NCT07279922","What is the Role of Triglyceride-glucose Index as a Predictive Marker for Insulin Resistance in Pre Diabetic Chronic Kidney Disease Patients?","The Role of Triglyceride-glucose Index as a Predictive Marker for Insulin Resistance in Pre Diabetic Chronic Kidney Disease Patients.","Inclusion Criteria:\n\n* Adults aged ≥18 years\n\nPatients with medical history free from renal dysfunction\n\nPatients with renal dysfunction (CKD stages 2\\_5 based on KDIGO guidelines)\n\nNo previous diagnosis of diabetes mellitus\n\nProvided informed consent\n\nExclusion Criteria:\n\n* Known type 1 or type 2 diabetes mellitus\n\nAcute kidney injury\n\nUse of steroids or medications that affect glucose and lipid metabolism\n\nPregnancy\n\nActive infections\n\nMalignancy",{"count":545,"type":22},60,"The aim of this study is to evaluate the role of the triglyceride-glucose (TyG) index as a predictive marker for insulin resistance in pre-diabetic patients with chronic kidney disease (CKD), and to investigate its potential utility as a simple, non-invasive alternative to traditional insulin resistance assessment methods.",[548,29],"Chronic Kidney Disease","2025-12-01",{"date":551,"type":34},"2025-12-12",{"date":553,"type":22},"2026-01-01",{"date":555,"type":22},"2028-03-01",{"name":557,"class":41},"Assiut University",{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":562,"acronym":563,"eligibilityCriteria":564,"healthyVolunteers":76,"sex":18,"minAge":565,"maxAge":178,"enrollmentInfo":566,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":568,"conditions":569,"keywords":571,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":579,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":587},"100602022","innodia-family--friends-early-stage-t1d-detection-protocol-100602022","NCT07118098","INNODIA Family & Friends Early-Stage T1D Detection Protocol","INNODIA DETECT","Inclusion Criteria:\n\n1. Have given written informed consent to participate\n2. Be aged between 1 and 45 years\n3. Have a family relative with T1D or close friend diagnosed with symptomatic T1D at age \\\u003C45 years\n\nExclusion Criteria:\n\n1. Previous diagnosis of stage 3 T1D or other forms of diabetes\n2. Unable\u002Funwilling to consent to participation","1 Year",{"count":567,"type":22},30000,"The purpose of INNODIA DETECT is to identify people who are at increased risk of developing T1D. Investigators are doing this by testing for markers in the blood (autoantibodies) that tell them an individuals risk of getting T1D in the future.\n\nWhat is Type 1 Diabetes (T1D)? T1D is a serious disease where the blood glucose (sugar) level is too high because the body cannot make a hormone called insulin.\n\nThis happens when the body's immune system attacks the cells in the pancreas that make insulin (called beta cells), meaning that insulin production stops.\n\nThis is harmful to the body as insulin does an essential job. It allows the glucose in the blood to enter cells and fuel the body, resulting in a lowering of the blood glucose level.\n\nWhat are Autoantibodies? T1D autoantibodies are markers found in the blood that indicate that the destruction of insulin producing cells has begun. The risk of developing T1D increases with the number of autoantibodies detected.\n\nPeople who have 1 autoantibody detected in their blood are at increased risk of developing T1D. The presence of 2 or more autoantibodies indicates that T1D is present but the individual does not show any signs or symptoms yet.\n\nHowever, these autoantibodies can be present for many years before someone develops symptoms of T1D. They often appear in the first few years of life.\n\nThe investigators are asking children and adults across Europe, aged between 1 and 45 years, who have either a family member (parent, child, full or half sibling) or close friend diagnosed with T1D before 45 years of age to provided a small blood sample so they can look at these T1D autoantibodies.\n\nIf a participant's autoantibody results are negative, this means they do not have autoantibodies and are at low risk of developing T1D. No further tests will be required, and they will exit the program.\n\nIf results indicate a participant has 1 or more positive T1D autoantibodies, a member of the clinical team will contact and invite them to the hospital for a venous blood sample to confirm the result. This confirmation test will be done as part of routine clinical care by the participants clinical team. INNODIA DETECT will end here and, if confirmed positive, the participant will be invited to attend further follow-up by entering in a separate protocol (named INNODIA MONITOR).",[570,29],"Type 1 Diabetes (T1D)",[572,573,574,575,576,577],"Type 1 diabetes","Autoantibodies","Screening","Pre-T1D","Stage 1","Stage 2","2025-11-25",{"date":580,"type":34},"2025-11-26",{"date":582,"type":34},"2025-06-25",{"date":584,"type":22},"2027-12",{"name":586,"class":41},"INNODIA iVZW",5,{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":593,"acronym":594,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":596,"targetDuration":4,"studyType":23,"phases":598,"briefSummary":600,"conditions":601,"keywords":604,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":106},"100550396","phase-1-prevention-of-progression-of-prediabetes-obesity-and-cv-risk-100550396","NCT06446531","Prevention of Progression of Prediabetes, Obesity and CV Risk","Pioneering and Affordable Strategies to Prevent Progression of Prediabetes, Obesity and CV Risk in Hispanics","Pre-DM","Inclusion Criteria:\n\n1. Patients will have an established diagnosis of pre-Diabetes Mellitus (DM) before the screening visit, documented by an acceptable modality in the last 6 months.\n2. Age ≥ 18 years old\n3. Body Mass Index (BMI)=25-40 kg\u002Fm2\n4. Glycated Hemoglobin (HbA1c) = 5.7-6.4%\n5. Blood Pressure (BP) \\\u003C160\u002F100\n6. Estimated Glomerular Filtration Rate (eGFR) ≥30 ml\u002Fmin•1.73m2\n7. Body weight must be stable (±5 pounds) over the last 3 months.\n8. Oral diuretics, if prescribed to the patient according to local guidelines and discretion of the investigator, should be stable for at least 1 week prior to randomization.\n9. Hispanic ethic group\n10. Willing to adhere to medication regimen for up to 6 months.\n11. Male or female, if female, met these criteria:\n\n    1. Not pregnant or breast-feeding\n    2. Negative pregnancy test result at visit 1 (screening)\n    3. During the entire study, women of childbearing potential (WOCBP) including peri-menopausal women who have a menstrual period within 1 year must practice appropriate, and effective birth control, either implants or pills, or a vasectomized partner prior to receiving the first dose of study medication\n12. Does not suffer from severe claustrophobia\n13. No contraindication for Magnetic Resonance Imaging (MRI) (metal plates, screws, shrapnel, pins, or cardiac pacemaker)\n\nExclusion Criteria:\n\n1. Patients currently on one of the selected therapies\n2. Extended diagnoses with Type 2 Diabetes\n3. Pregnancy, lactation, women of childbearing age (WOCBA) unwilling to use contraception\n4. Known allergy\u002Fsensitivity to study drugs or their ingredients\n5. Major oncologic diagnosis in the last 5 years\n6. Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements\n7. Inability or unwillingness of individual or legal guardian\u002Frepresentative to give written informed consent\n8. Major organ or metabolic diseases, or physical limitations that will not allow the subject to complete the study\n9. Myocardial infraction, coronary artery bypass graft surgery, or other major cardiovascular event in the past 60 days\n10. Heart transplant recipient or listed for a heart transplant\n11. Currently implanted left ventricular assist device\n12. Cardiomyopathy based on infiltrative or cumulative hypertrophic obstructive cardiomyopathy or known pericardial constriction\n13. Any severe (obstructive or regurgitant) valvular heart disease, expected to lead to surgery during the trial period\n14. Acute decompensated heart failure requiring intravenous diuretics, vasodilators, inotropic agents, or mechanical support within 1 week of screening and during the screening period prior to randomization\n15. Implanted cardioverter defibrillator within 3 months prior to screening\n16. Cardiac resynchronization therapy",{"count":597,"type":22},64,[599],"PHASE1","The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight. The investigators also want to reduce participants risk of heart problems. The study team will look at how these treatments affect metabolism and other body functions to help find new ways to treat diabetes and obesity in the future.",[121,602,603],"Weight, Body","Cardiovascular Diseases",[605,606,607],"Affordable strategies","Prevention of progression","Hispanic","2025-11-10",{"date":610,"type":34},"2025-11-12",{"date":612,"type":34},"2024-09-11",{"date":614,"type":22},"2027-07",{"name":616,"class":41},"The University of Texas Health Science Center at San Antonio",{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":622,"acronym":4,"eligibilityCriteria":623,"healthyVolunteers":12,"sex":18,"minAge":345,"maxAge":624,"enrollmentInfo":625,"targetDuration":4,"studyType":23,"phases":627,"briefSummary":628,"conditions":629,"keywords":630,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":106},"100396465","mechanisms-of-fatigability-with-diabetes-100396465","NCT04442451","Mechanisms of Fatigability With Diabetes","Mechanisms of Fatigability and the Protective Effects of Exercise in People With Diabetes","Inclusion Criteria:\n\n* Men and women adults 30 years to 85 years or less\n* Pre-diabetes \\[glycosylated hemoglobin (HbA1c) of 5.7-6.4% and fasting plasma glucose 100-125 mg\u002FdL at the time of initial screening\\]\n* Controls \\[normoglycemic with a HbA1c level ≤5.6% and fasting blood glucose ≤ 99 mg\u002FdL (5.5 mmol\u002FL)\\]\n* Type 2 Diabetes Mellitus \\[elevated glycosylated hemoglobin (HbA1c) \\>6.5% and \\\u003C10%\\]\n\nExclusion Criteria:\n\n* Signs or symptoms of neuropathy\n* Medications associated with advanced stages of T2D including insulin\n* Poor glycemic control (HbA1c\\>10%)\n* Peripheral edema\n* Severe obesity (BMI, \\>45kg·m-2)\n* Untreated hypothyroidism\n* Smoking\n* Hypertension\n* Cardiovascular or musculoskeletal disease that preclude exercise testing\n* Hormone replacement drugs or vasoactive medications","85 Years",{"count":626,"type":22},80,[25],"Pre-diabetes (Pre-D) is a precursor to type 2 diabetes (T2D) and characterized by increased exercise fatigability of lower limb muscles, that can impede exercise performance. The cause for the increased fatigability in people with Pre-D is not known. Given the profound vascular disease present in people who have had uncontrolled diabetes for several years, we will determine whether dynamic, fatiguing contractions of the lower limb muscles in people with Pre-D are limited by vascular dysfunction at multiple levels along the vascular tree including the artery, arteriole, and\u002For capillary. This clinical trial involves a novel exercise training regime involving blood flow restriction to the exercising limb will be used as a probe to further understand the vascular mechanisms for increased fatigability in people with Pre-D and T2D. The long-term goal is to better understand what limits exercise and functional performance in people with diabetes to help develop targeted, more effective exercise programs.",[56,184],[88,56,631,632,633,634],"Fatigability","Blood Flow Restriction Training","Vascular Function","Muscle Fatigue","2025-10-06",{"date":637,"type":34},"2025-10-08",{"date":639,"type":34},"2022-09-01",{"date":641,"type":22},"2027-08-31",{"name":643,"class":41},"University of Michigan",{"id":645,"slug":646,"hasResults":12,"nctId":647,"briefTitle":648,"officialTitle":648,"acronym":4,"eligibilityCriteria":649,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":650,"enrollmentInfo":651,"targetDuration":4,"studyType":23,"phases":652,"briefSummary":653,"conditions":654,"keywords":4,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":655,"lastUpdatePostDateStruct":656,"startDateStruct":658,"completionDateStruct":660,"leadSponsor":662,"locationsCount":4},"100608757","impact-of-partially-replacing-wheat-with-millets-or-bengal-gram-flour-in-rotis-on-glycemia-and-prediabetes-reversal-100608757","NCT07205705","Impact of Partially Replacing Wheat With Millets or Bengal Gram Flour in Rotis on Glycemia and Prediabetes Reversal","Inclusion Criteria:\n\n1. Age 18 to 60 years\n2. Prediabetes as diagnosed on oral glucose tolerance test (OGTT): Fasting blood glucose ≥100mg\u002Fdl and \\\u003C126 mg\u002Fdl and\u002For 2-h plasma glucose ≥140mg\u002Fdl and \\\u003C200mg\u002Fdl (after ingestion of 75 gram anhydrous oral glucose).\n\nExclusion Criteria:\n\n1. Acute infections and advanced end-organ damage\n2. History of hepatitis or pancreatitis, abnormal liver and renal functions\n3. Recent (\\\u003C3 months) changes in weight (≥5%) and\u002For weight-changing medications\n4. Any known allergy to wheat or any other grain\n5. Subjects with uncontrolled hypothyroidism or hypertension\n6. On any drug causing weight gain or weight loss","60 Years",{"count":450,"type":22},[25],"There is limited research on the impact of millets on glycemia, and it remains unclear whether partially replacing wheat in rotis with low glycemic index millets or Bengal gram flour offers greater glycemic benefits compared to whole wheat. This approach has the potential to reduce postprandial and overall glycemia, supporting the reversal of prediabetes through dietary modification alone. This study introduces a novel formulation of rotis using 50:50 blends of wheat with either barnyard millet, barley, or Bengal gram flour, aiming to improve glycemic control without compromising taste. Glycemic response is assessed through a combination of meal tolerance tests, continuous glucose monitoring, and a three-month dietary intervention, providing both immediate and long-term data. Additionally, the study includes a comprehensive metabolic evaluation by measuring serum insulin, inflammatory markers, and free fatty acids key indicators in the progression of prediabetes. Conducted as a randomized controlled trial with 80 participants across four arms (20 per arm), the study comprises three phases: Phase I evaluates immediate glycemic response through a meal tolerance test; Phase II uses continuous glucose monitoring over three days to monitor fluctuations in glucose levels; and Phase III, with 140 participants, assesses the long-term impact of the dietary intervention over three months. The primary objectives are to determine the effect of the interventions on glycemic response and HbA1c, with an expected outcome of a 10% reduction in the area under the curve for overall and postprandial glucose in Phases I and II, and a 10% reduction in HbA1c in Phase III.",[29],"2025-09-25",{"date":657,"type":34},"2025-10-03",{"date":659,"type":22},"2025-11-15",{"date":661,"type":22},"2027-11-20",{"name":663,"class":41},"Diabetes Foundation, India",{"id":665,"slug":666,"hasResults":12,"nctId":667,"briefTitle":668,"officialTitle":668,"acronym":669,"eligibilityCriteria":670,"healthyVolunteers":12,"sex":18,"minAge":671,"maxAge":50,"enrollmentInfo":672,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":674,"conditions":675,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":677,"lastUpdatePostDateStruct":678,"startDateStruct":680,"completionDateStruct":682,"leadSponsor":684,"locationsCount":106},"100602580","uk-islet-autoantibody-registry-100602580","NCT07125365","UK Islet Autoantibody Registry","UKIAb Registry","Inclusion Criteria:\n\n* Male or female, aged 6 months - 70 years\n* IAb positive (≥ 1) to any of the following: insulin\u002FGAD\u002FIA2\u002FZnT8, confirmed in a reference laboratory.\n* Participant is willing and able to give informed consent for participation in the study (≥ 16 years old), or for \\\u003C 16 years, parental\u002Fguardian consent (plus assent, where appropriate)\n* Living in the UK\n* For ADDRESS-2 participants only: have taken part in a blood draw as part of ADDRESS-2\n* For the qualitative interviews: Have been living with (or is a parent\u002Fguardian of a child who has been living with) a positive IAb result for ≥ 6 months.\n\nExclusion Criteria:\n\n* Ongoing subcutaneous insulin requirement","6 Months",{"count":673,"type":22},350,"Type 1 diabetes (T1D) is a life-long condition where the immune system destroys part of the body (the pancreas) which makes the chemical, insulin. Insulin is needed to control blood sugar levels. Treatment involves life-long insulin replacement by injection or insulin pump.\n\nPrevious research has shown that the development of T1D occurs through different stages. This starts with a phase where there are no symptoms, which can last months or years, before symptoms of T1D develop and a person becomes unwell. The risk of developing T1D increases with presence of markers in the blood called islet autoantibodies. The risk of developing T1D increases with presence of markers in the blood called islet autoantibodies (IAb). Children with two or more IAb have an 80-90% chance of developing T1D within 15 years. It is almost certain that they will develop the condition in their lifetime. Children with only one IAb have a much lower risk of developing T1D (around 15%). Less is understood about the natural history of being IAb positive in adults, and the investigators hope this study will help them understand more.\n\nThe aim of the research is to understand what it is like to live with being at risk of T1D, what information and support people need, and whether they use NHS services more than others, for example due to being anxious about developing T1D. The investigators will work with the public and patient involvement group using information from the research and, with the charity Diabetes UK, to create a policy statement about the type of care that is needed to support these individuals.\n\nTo be able to do this research, tbhe investigators need first to recruit these rare individuals into one single registry of children, young people and adults who have islet autoantibodies in their blood. This will also allow the invetigators to collect data from individuals in the registry to compare this to data from other countries, to help understand why people progress from being islet autoantibody positive to requiring insulin in the UK.\n\nPeople entering the registry will also be told if a drug is licensed in the UK to help delay T1D onset. Participants can also consent to be contacted about any research studies, which are testing drugs or interventions to prevent or delay the start of T1D.",[570,676,56,574],"Registry","2025-08-08",{"date":679,"type":34},"2025-08-15",{"date":681,"type":34},"2025-07-11",{"date":683,"type":22},"2027-05-31",{"name":685,"class":41},"University of Oxford"]